SCHEMBL4258659

SCHEMBL4258659

O=S(=O)(c1ccc(/C=C/c2ccc(O)c(O)c2)cc1)N1CCCCC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.75
MAPK1 P28482 3/20 0.75
USP2 O75604 2/20 0.75
KDM4E B2RXH2 2/20 0.75
MEN1 O00255 2/20 0.75
KMT2A Q03164 2/20 0.75
LMNA P02545 2/20 0.75
JAK2 O60674 1/20 0.75
ALDH1A1 P00352 1/20 0.75
POLB P06746 1/20 0.75
GAA P10253 1/20 0.75
THRB P10828 1/20 0.75
HPGD P15428 1/20 0.75
ALOX12 P18054 1/20 0.75
HTT P42858 1/20 0.75
L3MBTL1 Q9Y468 1/20 0.75
SERPINE1 P05121 1/20 0.51
EGFR P00533 1/20 0.50
ALOX5 P09917 1/20 0.49
MAOB P27338 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258660 1.00 MAPT (0.75) MAPTMAPK1USP2KDM4EMEN1
SCHEMBL4259089 0.86 L3MBTL1 (0.60) MAPTMAPK1USP2KDM4EMEN1
SCHEMBL4259087 0.86 L3MBTL1 (0.60) MAPTMAPK1USP2KDM4EMEN1
SCHEMBL25198504 0.86 MAPT (1.00) MAPTMAPK1USP2KDM4EMEN1
SCHEMBL25218049 0.86 MAPT (1.00) MAPTMAPK1USP2KDM4EMEN1
SCHEMBL25216325 0.86 MAPT (1.00) MAPTMAPK1USP2KDM4EMEN1
SCHEMBL4469033 0.83 SERPINE1 (0.72) MAPTMAPK1USP2KDM4EMEN1
SCHEMBL27743683 0.77 USP2 (0.67) MAPK1USP2MEN1KMT2ALMNA
SCHEMBL4262069 0.77 GPBAR1 (0.64) MAPTMAPK1USP2KDM4EMEN1
SCHEMBL4262072 0.77 GPBAR1 (0.64) MAPTMAPK1USP2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106014-A1 Methods for treating diabetes ELI LILLY AND COMPANY 2006-05-18 US claimed
WO-2006044556-A2 DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES GALILEO PHARMACEUTICALS, INC. (US) 2006-04-27 WO claimed
US-7629375-B2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2009-12-08 US disclosed
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2006-08-10 US disclosed
US-20060106014-A1 Methods for treating diabetes ELI LILLY AND COMPANY 2006-05-18 US disclosed
WO-2006044556-A2 DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES GALILEO PHARMACEUTICALS, INC. (US) 2006-04-27 WO disclosed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP disclosed
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER INC. 2005-06-30 US disclosed
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2005-05-26 US disclosed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP disclosed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US disclosed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106014-A1 Methods for treating diabetes ALOX5, ALOX15, ALOX15B MAPT 4841/4885MAPK1 4119/4885USP2 2170/4885
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 MAPT 2548/4885MAPK1 2696/4885USP2 3054/4885
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 MAPT 2548/4885MAPK1 2696/4885USP2 3054/4885
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 MAPT 2548/4885MAPK1 2696/4885USP2 3054/4885
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 MAPT 2548/4885MAPK1 2696/4885USP2 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.